Page last updated: 2024-12-06

pneumocandin c(0)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pneumocandin C(0) is a cyclic lipopeptide natural product with antifungal activity. It is a member of the echinocandin class of antifungal agents, which inhibit the synthesis of β-1,3-glucan, an essential component of fungal cell walls. Pneumocandin C(0) is produced by the fungus *Glarea lozoyensis*. It has shown potent in vitro and in vivo activity against a broad range of pathogenic fungi, including *Candida*, *Aspergillus*, and *Cryptococcus*. The compound has also been studied for its potential use in the treatment of invasive fungal infections in immunocompromised patients. The synthesis of Pneumocandin C(0) has been extensively investigated, and several synthetic routes have been developed. The molecule has a complex structure, and its synthesis poses a significant challenge. Research on Pneumocandin C(0) is ongoing, with studies focused on optimizing its synthesis, improving its pharmacokinetic properties, and exploring its potential therapeutic applications.'

pneumocandin C(0): structure given in first source; isolated from Zalerion arboricola [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72974
SCHEMBL ID1162942
MeSH IDM0212694

Synonyms (8)

Synonym
144074-96-4
n-[[(1r)-3-amino-1-hydroxy-3-oxo-propyl]-[(2r)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-tetrahydroxy-[(1r)-1-hydroxyethyl]-hexaoxo-[?]yl]-10,12-dimethyl-tetradecanamide
pneumocandin co
pneumocandin bo, 6-(trans-4-hydroxy-l-proline)-
pneumocandin c(0)
SCHEMBL1162942
n-[(3s,6s,9s,11r,15s,20s,21r,24s,26r)-3-[(1r)-3-amino-1-hydroxy-3-oxopropyl]-6-[(2r)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,26-tetrahydroxy-15-[(1r)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-
EX-A3229
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's4 (80.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]